Monoclonal Antibodies for Cancer Treatment

Request Number N235443
Need details

Pfizer seeks to collaborate with organizations that have monoclonal antibodies (mAb) suitable for antibody drug conjugation (ADC). Pfizer has two decades of experience in developing therapies based on antibody drug conjugation and have developed an extensive set of proprietary linkers and payloads that can be leveraged for this collaboration.


Pfizer would like to conjugate their linkers and payloads to your mAb and provide you with ADC materials to test in your in vitro and in vivo models.


Key Success Criteria:

To be considered for the ADC approach, monoclonal antibodies will demonstrate the following capabilities:

    • Partner must be able to supply 250 mg amount of mAb
    • Tumor selective expression of the target antigen, with no or minimal normal tissue presence, typically demonstrated by IHC
    • Demonstrated cell surface presentation of the antigen, typically by FACS
    • Demonstrated ability of the monoclonal antibody to induce internalization of the antibody-antigen complex and transit through the lysozome
    • Ability to kill cancer cells in cell culture via either direct or indirect drug conjugation (e.g., Saporin Fab ZAP assay)
    • Rodent cross reactivity to the target antigen is a distinct advantage for toxicology studies
    • Humanized antibodies are also preferred


Approaches Not of Interest:

Pfizer is not currently interested in assessing mAbs that do not target cancer cells or in assessing mAbs that cannot be generated in sufficient quantity to enable conjugation.


Preferred Collaboration Type:

Pfizer seeks to evaluate your mAb for potential utility as an ADC under a material evaluation agreement.


Pfizer will conjugate their linkers and payloads to your mAb and provide you with ADC materials to test in your in vitro and in vivo models.  As no single linker/payload combination will work for all ADC targets, access to Pfizer's extensive set of next generation linkers and payloads will improve the chance that your mAb will succeed as an ADC.


Strong signs of efficacy and safety may lead to a further research collaboration with the aim of rapidly progressing towards entry into clinical studies.


IP Requirements:

The partner organization must hold full rights to license (or sublicense) the mAb that are tested.


How to Respond:

We are looking for a completed Response Template, which may contain a concise abstract/executive summary. The proposal should briefly describe the technical approach and provide information on technology performance, background and description of the responding team and their related experience. To Respond, please use the red Respond Now button located to the right. Please note that only non-confidential information can be accepted.


By submitting a response you represent that the response does not contain and will not be deemed to contain any confidential information of any kind whatsoever. All Personal Information disclosed to Pfizer within a response will be utilized in accord with principles and polices as described at By submitting a response, you also acknowledge and confirm that you have consulted with your Technology Transfer Office, Business Development Office or any other required group and that you have their approval to submit the response. By submitting a response, you acknowledge that the Need's sponsoring organization, in its sole discretion, may select or reject a response or any portion thereof.


Your NineSights community profile should contain all required information in order to provide us with appropriate contact information for your responses. For questions about NineSights privacy and security, please feel free to post in our forums.

Migrated from previous NineSights Community Site
Key Success Criteria
Migrated from previous NineSights Community Site
Preferred Collaboration types
  • Supply Agreement
Point of Contact
Jonathan Tzeng
Area of Interest
  • Chemical Manufacturing
  • Food & Beverage
  • Manufacturing & Fabrication
  • Medical Products & Services
  • Other
Due Date
April 11, 2014
Award Amount
This page does not have file attachments.
This page does not have file attachments.